(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Byung Ha Chung discussing the efficacy and safety of apalutamide use in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC). In TITAN study, the addition of apalutamide to androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) for mCSPC patients.1 Given that there may be regional differences in outcomes as part of global phase 3 trial, Dr. Chung and colleagues performed this TITAN Asian subgroup analysis with the results reported today at the ESMO 2021 congress.